Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00911898 · ClinicalTrials.gov registry record · Phase 1
A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers
A Phase 1 study of Metastatic Breast Cancer and Her2 Amplified Solid Tumors, sponsored by Merrimack Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 4
- Study locations
NCT00911898 is a Phase 1 study of Metastatic Breast Cancer and Her2 Amplified Solid Tumors that has completed, run by Merrimack Pharmaceuticals. The registered enrollment target is 20 participants, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (90% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT00911898, a Phase 1 study of Metastatic Breast Cancer and Her2 Amplified Solid Tumors, has completed, sponsored by Merrimack Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is an open-label Phase 1 trial of MM-111.
Conditions Studied
Interventions
- DRUG MM-111
Study Locations (4)
California
- University of Southern California Norris Comprehensive Cancer Center - Los Angeles
Indiana
- Indiana University (IUPUI) - Indianapolis
Pennsylvania
- Fox Chase Center - Philadelphia
Texas
- South Texas Accelerated Research Therapeutics - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2009-06 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00911898
The ClinicalTrials.gov registry entry for NCT00911898 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Merrimack Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which MM-111 is the first listed.
NCT00911898 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Indiana, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00911898 about?
NCT00911898 is a clinical study titled "A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers". This study is an open-label Phase 1 trial of MM-111.
What is the current status of trial NCT00911898?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2009-06. Estimated completion is 2012-03.
What conditions does trial NCT00911898 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer, Her2 Amplified Solid Tumors.
What interventions are being tested in trial NCT00911898?
The interventions under investigation include: MM-111 (DRUG).
Who is sponsoring clinical trial NCT00911898?
This trial is sponsored by Merrimack Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00911898 being conducted?
This trial has 4 study locations across California, Indiana, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
RECRUITING · Phase 1
-
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
RECRUITING · Phase 1
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
-
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.